Cleveland, Ohio – September 14, 2026 – SPR, part of Medtronic, announced that Humana, Peak Health, and three Managed Medicaid plans have updated their medical policies designating the SPRINT® PNS System as a covered treatment option for patients who meet the applicable policy criteria. The shift to broaden peripheral nerve stimulation (PNS) coverage for members is a significant step forward in expanding access to non-surgical, minimally invasive pain management options. Combined, these plan decisions represent 10 million covered lives who may be eligible for SPRINT PNS.
Participating health plans
The following payers have initiated coverage of the SPRINT PNS System for their members:
- Humana Medicare Advantage – Serving approximately 8.2M members across the United States. Coverage effective August 2026. The current coverage policy is searchable via their coverage library here.
- Keystone First VIP, AmeriHealth, Select Health SC – Serving approximately 1.8M Managed Medicaid members across DE, FL, LA, MI, NH, NC, OH, PA, SC, and DC. Coverage effective April 2026. The current coverage policy is available here.
- Peak Health – Serving approximately 12,000 Medicare Advantage members across WV, PA, KY and VA. Additionally, over 40,000 employees across three hospital systems are also eligible for commercial Peak Health insurance. Coverage effective July 2026. The current coverage policy is available here.
Coverage details
Under each plan’s updated medical policy, the SPRINT PNS System is now a covered therapy for the treatment of chronic, intractable pain when medically necessary and coverage criteria is met. Patients and providers are encouraged to verify individual plan criteria prior to treatment.
Specifically, Humana Medicare’s updated policy states that:
- Coverage for SPRINT PNS will be determined using Noridian’s Local Coverage Determination (LCD) medical necessity criteria, which is the language that applies to all PNS therapies
- The requirement for a successful percutaneous stimulation trial does not apply to the SPRINT PNS System because it is a temporary 60-day peripheral nerve stimulation device SPRINT is not intended to be used as a screening trial prior to permanent implantation
Keystone First VIP, AmeriHealth, and Select Health SC, all follow the same coverage policy titled Percutaneous Peripheral Nerve Stimulators for Chronic Nerve Pain, which was updated to designate 60-day percutaneous peripheral nerve stimulation (PNS) as medically necessary when the coverage criteria are met as set forth in the updated coverage policy. This revision reflects a comprehensive review of clinical guideline recommendations supporting the use of temporary 60-day PNS for both trial and treatment purposes. SPRINT PNS is the only therapy that is FDA cleared to offer temporary, 60-day PNS treatment.
Lastly, Peak Health’s policy, applicable to Medicare Advantage and Commercial patients, considers PNS medically necessary when the coverage criteria outlined in the medical policy is met.
Growing momentum
This series of positive coverage decisions follows recent national coverage determinations by payers, including Aetna, to cover SPRINT PNS. These wins reflect the strength of the clinical evidence supporting SPRINT PNS' efficacy, along with influential professional society guidelines that have helped shape coverage criteria across a range of pain etiologies.
“Each positive coverage decision represents meaningful progress for patients and providers seeking access to SPRINT PNS,” said Todd Davis, Vice President of Market Access at SPR. “We’re encouraged by the growing recognition among health plans of the clinical evidence supporting 60-day PNS and remain committed to working with payers, providers, and professional societies to expand access to this important option for people living with chronic pain.
For additional details on coverage for these payers or other health insurance plans, please contact SPR’s Reimbursement Team at [email protected].
SPR Contact
Dave Folkens
Public Relations
[email protected]
612.978.6547